Developer docs
API playgroundTry for free, no card

Search company profiles

Vipergen

Full company profile

uuid000b9ds

Namestring
Vipergen
Legal namestring
Vipergen ApS
Websiteurl
vipergen.com
Company typeenum
Private
Founded yearint
2005
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
DNA-encoded library screening, small molecule drug discovery, hit identification services, molecular glue discovery, DEL screening technology
Industry2 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Fee-For-Service Drug Discovery Services
TypeProfessional Services
Description

Vipergen offers straightforward Fee-For-Service arrangements for DEL screening and drug discovery projects. Clients pay for screening services delivered by Vipergen's proprietary technology platforms.

vipergen.com
2Integrated Drug Discovery Partnership
TypeProfessional Services
Description

Comprehensive joint ventures and funded discovery partnerships with pharmaceutical and biotechnology companies. Vipergen provides its proprietary suite of DEL technologies through funded discovery partnerships, including top pharmaceutical companies in the USA, EU, and Japan.

vipergen.com
3DEL Series Products
TypeOne Time License
Description

Vipergen launched DEL series products including Lib100 and Lib058 (updated Series 50), offered as part of collaborative arrangements with partners such as Aurigene Pharmaceutical Services Ltd.

vipergen.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1YoctoReactor (yR)
Description

Proprietary 2nd-generation library synthesis technology ensuring high fidelity with 100% match between DNA code and compound.

vipergen.com
+6 more records
Core offering1 text field

Vipergen provides small molecule drug discovery services built on its proprietary DNA-encoded library (DEL) screening platforms: YoctoReactor (yR) for library synthesis, Binder Trap Enrichment (BTE) for in vitro screening, and Cellular Binder Trap Enrichment (cBTE) for screening directly inside living cells. The company delivers hit identification, lead generation, and specialized services such as molecular glue discovery, PPI inhibitor discovery, selectivity profiling, and targeted protein degradation to pharmaceutical and biotechnology clients worldwide. Engagements are structured as Fee-For-Service projects or funded discovery partnerships and joint ventures.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 8-12 weeks from target to hits (vs 6-18 months for traditional HTS)
+5 more records
Product overview1 text field

Vipergen is a world-leading provider of small molecule drug discovery services based on DNA-encoded library (DEL) technologies. The company offers a platform of three proprietary technologies: YoctoReactor (YR) for high-fidelity library synthesis, Binder Trap Enrichment (BTE) for solution-based in vitro screening, and Cellular Binder Trap Enrichment (cBTE) for screening directly in living cells. Services include DEL screening in both living cells and in vitro formats, with specialized offerings such as Molecular Glue Direct for targeted protein degradation, PPI Inhibitor Direct, Selectivity Direct, Express (fast turnaround), and Snap (affordable option). DEL series products include Lib100 and Lib058. The company provides flexible partnership models from Fee-For-Service to comprehensive joint ventures.

Product and service12 records
1YoctoReactor (yR) Libraries
CategoryCore Technology Platform
Description

Proprietary 2nd generation library synthesis technology for high-fidelity DNA-encoded library construction with 100% match between DNA code and compound, using designer building blocks for superior chemical diversity.

2Binder Trap Enrichment (BTE)
CategoryCore Technology Platform
Description

Proprietary 2nd generation screening technology using a solution-based homogeneous assay with no matrix binders and no target denaturation, providing low false positive rates for binder identification.

3Cellular Binder Trap Enrichment (cBTE)
CategoryCore Technology Platform
Description

Proprietary 3rd generation screening technology that enables DEL screening directly inside living cells without requiring purified target protein, providing physiologically relevant conditions, multiplexing, and broader protein target space.

4DELs in Living Cells Screening
CategoryScreening Service
Description

DNA-encoded library screening service performed inside living cells using cBTE technology, enabling target screening without purified protein and in physiologically relevant conditions.

5DELs in Vitro Screening
CategoryScreening Service
Description

DNA-encoded library screening service using BTE technology in a solution-based format for targets that can be purified.

6DELs in Cells - Molecular Glue Direct
CategorySpecialized Screening Service
Description

Direct molecular glue discovery service using multiplexed cBTE screening in living cells with E3 ubiquitin ligases, enabling discovery of molecules that induce POI-E3 ligase interactions for targeted protein degradation.

7DELs in Cells - PPI Inhibitor Direct
CategorySpecialized Screening Service
Description

Service for direct discovery of protein-protein interaction inhibitors using cellular screening format.

8DELs in Cells - Selectivity Direct
CategorySpecialized Screening Service
Description

Multiplexed screening service enabling simultaneous screening of target and anti-targets for selectivity profiling.

9DELs in Cells - Express
CategoryScreening Service
Description

Fast turnaround-time DEL screening service optimized for rapid hit identification.

10DELs in Cells - Snap
CategoryScreening Service
Description

Easy, fast, and affordable DEL screening service designed for smaller biotech companies with limited budgets, providing full screening packages with predefined, optimized setup.

11Lib100 DEL Series
CategoryDEL Library Product
Description

New DNA-encoded library series product launched as part of Vipergen's strategic partnership with Aurigene Pharmaceutical Services.

12Lib058 DEL Series
CategoryDEL Library Product
Description

Updated DNA-encoded library series (renamed from Series 50) launched as part of Vipergen's strategic partnership with Aurigene Pharmaceutical Services.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Aurigene Pharmaceutical Services Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

Strategic partnership to offer DNA encoded library (DEL) screening and integrated drug discovery services to clients. Vipergen launched new DEL series products including Lib100 and Lib058 (updated Series 50) as part of this collaboration. Partnership offers flexible structures ranging from Fee-For-Service arrangements to comprehensive joint ventures.

vipergen.com
Strategic tierSupportingTypeTechnology or Integration
Description

Partnership page listing on Vipergen's website indicating collaboration in the drug discovery ecosystem. Nature of technical collaboration not fully detailed in available sources.

Strategic tierSupportingTypeTechnology or Integration
Description

Partnership page listing on Vipergen's website indicating a collaborative relationship in the drug discovery ecosystem.

Strategic tierSupportingTypeOthers
Description

Supplier of custom peptide and peptide conjugates, listed as part of Vipergen's supplier network.

5BioNordika
Strategic tierSupportingTypeOthers
Description

Supplier of high-quality reagents and chemicals for molecular biology, protein analysis, and cell-based applications, listed as part of Vipergen's supplier network.

vipergen.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the largest dedicated DNA-encoded library (DEL) discovery providers, offering both DEL synthesis and screening services to pharma and biotech — directly comparable to Vipergen's core DEL screening business. Now part of Evotec, giving it substantially greater scale and capital than Vipergen.

TypeDirect peer
Description

Publicly listed DEL-based drug discovery company operating DEL screening, targeted protein degradation (including molecular glues via its subsidiary Vernalis), and partnered discovery programs — overlapping with Vipergen on DEL screening services and molecular glue discovery.

TypeDirect peer
Description

Swiss-based DEL technology and service provider with proprietary DNA-encoded chemistry and screening platforms serving pharma clients — a directly comparable niche DEL services competitor.

TypeDirect peer
Description

Hungarian DEL technology company offering DNA-encoded library synthesis and screening services to pharma and biotech — closely comparable in scale and service orientation to Vipergen.

TypeEmerging player
Description

Emerging DEL platform company with proprietary DNA-encoded chemistry and a focus on challenging drug targets; competing with Vipergen for the same early-discovery service engagements.

TypeBroad incumbent
Description

Global CRO/CDMO with significant DNA-encoded library and drug discovery service capabilities, serving the same large-pharma customers as Vipergen but at much greater scale and with a far broader service portfolio.

7Aurigene Pharmaceutical Services
TypeOthers
Description

Vipergen's 2025 strategic partner for integrated DEL screening and drug discovery services, also operating its own discovery and CDMO offerings — partly a collaboration channel and partly a competitor in integrated drug discovery services.

8Nuevolution (Amgen)
TypeOthers
Description

Historical DEL competitor (acquired by Amgen in 2019) whose affiliated entity challenged Vipergen's cBTE patent at the EPO in 2026 — represents the in-house DEL capability of a major pharma that also purchases external DEL services.

TypeBroad incumbent
Description

Large CRO offering hit identification, medicinal chemistry, and DEL-related services to pharma and biotech — overlapping with Vipergen on drug discovery services, particularly for small biotech and mid-market pharma.

TypeBroad incumbent
Description

Large contract drug discovery and development organization owning X-Chem (DEL) and offering end-to-end services across target ID through IND — competes with Vipergen both directly via X-Chem's DEL platform and as a broad discovery outsourcing incumbent.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks2 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vipergen

Drug Discovery Servicesvipergen.com

Vipergen firmographics

Firmographics
Name
Vipergen
Legal name
Vipergen ApS
Website
https://vipergen.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Vipergen industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • DNA-encoded library screening
  • Small molecule drug discovery
  • Hit identification services
  • Molecular glue discovery
  • DEL screening technology

Where Vipergen is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Vipergen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Fee-For-Service Drug Discovery Services: Vipergen offers straightforward Fee-For-Service arrangements for DEL screening and drug discovery projects. Clients pay for screening services delivered by Vipergen's proprietary technology platforms.
  2. Integrated Drug Discovery Partnership: Comprehensive joint ventures and funded discovery partnerships with pharmaceutical and biotechnology companies. Vipergen provides its proprietary suite of DEL technologies through funded discovery partnerships, including top pharmaceutical companies in the USA, EU, and Japan.
  3. DEL Series Products: Vipergen launched DEL series products including Lib100 and Lib058 (updated Series 50), offered as part of collaborative arrangements with partners such as Aurigene Pharmaceutical Services Ltd.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Vipergen product offering

Product offering

Core offering

Vipergen provides small molecule drug discovery services built on its proprietary DNA-encoded library (DEL) screening platforms: YoctoReactor (yR) for library synthesis, Binder Trap Enrichment (BTE) for in vitro screening, and Cellular Binder Trap Enrichment (cBTE) for screening directly inside living cells. The company delivers hit identification, lead generation, and specialized services such as molecular glue discovery, PPI inhibitor discovery, selectivity profiling, and targeted protein degradation to pharmaceutical and biotechnology clients worldwide. Engagements are structured as Fee-For-Service projects or funded discovery partnerships and joint ventures.

Product overview

Vipergen is a world-leading provider of small molecule drug discovery services based on DNA-encoded library (DEL) technologies. The company offers a platform of three proprietary technologies: YoctoReactor (YR) for high-fidelity library synthesis, Binder Trap Enrichment (BTE) for solution-based in vitro screening, and Cellular Binder Trap Enrichment (cBTE) for screening directly in living cells. Services include DEL screening in both living cells and in vitro formats, with specialized offerings such as Molecular Glue Direct for targeted protein degradation, PPI Inhibitor Direct, Selectivity Direct, Express (fast turnaround), and Snap (affordable option). DEL series products include Lib100 and Lib058. The company provides flexible partnership models from Fee-For-Service to comprehensive joint ventures.

Differentiator

Problem solved

Functional benefit

Brands

  • YoctoReactor (yR): Proprietary 2nd-generation library synthesis technology ensuring high fidelity with 100% match between DNA code and compound.
  • Binder Trap Enrichment (BTE)
  • Cellular Binder Trap Enrichment (cBTE)
  • DELs in Cells – Molecular Glue Direct
  • DELs in Cells – Express
  • DELs in Cells – Snap
  • DELs in Cells – PPI Inhibitor Direct

Products and services

  • YoctoReactor (yR) Libraries Proprietary 2nd generation library synthesis technology for high-fidelity DNA-encoded library construction with 100% match between DNA code and compound, using designer building blocks for superior chemical diversity.
  • Binder Trap Enrichment (BTE) Proprietary 2nd generation screening technology using a solution-based homogeneous assay with no matrix binders and no target denaturation, providing low false positive rates for binder identification.
  • Cellular Binder Trap Enrichment (cBTE) Proprietary 3rd generation screening technology that enables DEL screening directly inside living cells without requiring purified target protein, providing physiologically relevant conditions, multiplexing, and broader protein target space.
  • DELs in Living Cells Screening DNA-encoded library screening service performed inside living cells using cBTE technology, enabling target screening without purified protein and in physiologically relevant conditions.
  • DELs in Vitro Screening DNA-encoded library screening service using BTE technology in a solution-based format for targets that can be purified.
  • DELs in Cells - Molecular Glue Direct Direct molecular glue discovery service using multiplexed cBTE screening in living cells with E3 ubiquitin ligases, enabling discovery of molecules that induce POI-E3 ligase interactions for targeted protein degradation.
  • DELs in Cells - PPI Inhibitor Direct Service for direct discovery of protein-protein interaction inhibitors using cellular screening format.
  • DELs in Cells - Selectivity Direct Multiplexed screening service enabling simultaneous screening of target and anti-targets for selectivity profiling.
  • DELs in Cells - Express Fast turnaround-time DEL screening service optimized for rapid hit identification.
  • DELs in Cells - Snap Easy, fast, and affordable DEL screening service designed for smaller biotech companies with limited budgets, providing full screening packages with predefined, optimized setup.
  • Lib100 DEL Series New DNA-encoded library series product launched as part of Vipergen's strategic partnership with Aurigene Pharmaceutical Services.
  • Lib058 DEL Series Updated DNA-encoded library series (renamed from Series 50) launched as part of Vipergen's strategic partnership with Aurigene Pharmaceutical Services.

Quantifiable outcome

  • 8-12 weeks from target to hits (vs 6-18 months for traditional HTS)
  • +5 more outcomes

Companies that use Vipergen

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Vipergen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Vipergen partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and supporting.

  • Aurigene Pharmaceutical Services Ltd.coreStrategic or Co-development Partner · 1 May 2025Strategic partnership to offer DNA encoded library (DEL) screening and integrated drug discovery services to clients. Vipergen launched new DEL series products including Lib100 and Lib058 (updated Series 50) as part of this collaboration. Partnership offers flexible structures ranging from Fee-For-Service arrangements to comprehensive joint ventures.
  • SARomics BiostructuressupportingTechnology or IntegrationPartnership page listing on Vipergen's website indicating collaboration in the drug discovery ecosystem. Nature of technical collaboration not fully detailed in available sources.
  • Boo Kyung S.M Co.supportingTechnology or IntegrationPartnership page listing on Vipergen's website indicating a collaborative relationship in the drug discovery ecosystem.
  • LifeTeinsupportingOthersSupplier of custom peptide and peptide conjugates, listed as part of Vipergen's supplier network.
  • BioNordikasupportingOthersSupplier of high-quality reagents and chemicals for molecular biology, protein analysis, and cell-based applications, listed as part of Vipergen's supplier network.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Vipergen competitors and assessment

Company assessment

Direct peers

  • X-Chem (Evotec): One of the largest dedicated DNA-encoded library (DEL) discovery providers, offering both DEL synthesis and screening services to pharma and biotech — directly comparable to Vipergen's core DEL screening business. Now part of Evotec, giving it substantially greater scale and capital than Vipergen.
  • HitGen: Publicly listed DEL-based drug discovery company operating DEL screening, targeted protein degradation (including molecular glues via its subsidiary Vernalis), and partnered discovery programs — overlapping with Vipergen on DEL screening services and molecular glue discovery.
  • Philochem: Swiss-based DEL technology and service provider with proprietary DNA-encoded chemistry and screening platforms serving pharma clients — a directly comparable niche DEL services competitor.
  • ComInnex: Hungarian DEL technology company offering DNA-encoded library synthesis and screening services to pharma and biotech — closely comparable in scale and service orientation to Vipergen.

Emerging players

  • DyNAbind: Emerging DEL platform company with proprietary DNA-encoded chemistry and a focus on challenging drug targets; competing with Vipergen for the same early-discovery service engagements.

Broad incumbents

  • WuXi AppTec: Global CRO/CDMO with significant DNA-encoded library and drug discovery service capabilities, serving the same large-pharma customers as Vipergen but at much greater scale and with a far broader service portfolio.
  • ChemPartner: Large CRO offering hit identification, medicinal chemistry, and DEL-related services to pharma and biotech — overlapping with Vipergen on drug discovery services, particularly for small biotech and mid-market pharma.
  • Evotec: Large contract drug discovery and development organization owning X-Chem (DEL) and offering end-to-end services across target ID through IND — competes with Vipergen both directly via X-Chem's DEL platform and as a broad discovery outsourcing incumbent.

Others

  • Aurigene Pharmaceutical Services: Vipergen's 2025 strategic partner for integrated DEL screening and drug discovery services, also operating its own discovery and CDMO offerings — partly a collaboration channel and partly a competitor in integrated drug discovery services.
  • Nuevolution (Amgen): Historical DEL competitor (acquired by Amgen in 2019) whose affiliated entity challenged Vipergen's cBTE patent at the EPO in 2026 — represents the in-house DEL capability of a major pharma that also purchases external DEL services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks2 records

Key highlights7 records

Customer concentration

Vipergen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vipergen leadership team

Management profile

Number of profiles

Profiles5 records

Vipergen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vipergen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vipergen

What does Vipergen do?

Vipergen provides small molecule drug discovery services built on its proprietary DNA-encoded library (DEL) screening platforms: YoctoReactor (yR) for library synthesis, Binder Trap Enrichment (BTE) for in vitro screening, and Cellular Binder Trap Enrichment (cBTE) for screening directly inside living cells. The company delivers hit identification, lead generation, and specialized services such as molecular glue discovery, PPI inhibitor discovery, selectivity profiling, and targeted protein degradation to pharmaceutical and biotechnology clients worldwide. Engagements are structured as Fee-For-Service projects or funded discovery partnerships and joint ventures.

Is Vipergen a public or private company?

Vipergen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Vipergen founded?

Vipergen was founded in 2005. It employs 11 to 50 people.

Where is Vipergen based?

Vipergen is headquartered in Copenhagen, Denmark, in the Europe region.

How does Vipergen make money?

Three revenue lines are on record. Fee-For-Service Drug Discovery Services are the primary driver. The others are integrated Drug Discovery Partnership and DEL Series Products.

Who are Vipergen's main competitors?

Direct peers on record are X-Chem (Evotec), HitGen, Philochem and ComInnex. DyNAbind is listed as an emerging player. Broad incumbents are WuXi AppTec, ChemPartner and Evotec. Others are Aurigene Pharmaceutical Services and Nuevolution (Amgen).

Does Vipergen have an API?

No public API is recorded for Vipergen.

What industry is Vipergen in?

Vipergen's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
VipergenPioneer in Fast Drug DiscoveryAurigene Pharmaceutical Services Ltd. and Vipergen have announced a strategic partnership to offer DNA encoded library (DEL) screening and integrated drug discovery services to clients. As part of the collaboration, Vipergen launched new DEL series products including Lib100 and an updated Series 50 renamed Lib058. The partnership offers flexible structures ranging from Fee-For-Service arrangements to comprehensive joint ventures.ContractpharmaAurigene & Vipergen Partner to Co-Market & Offer DEL Screening Technologies to CustomersAurigene and Vipergen partnered to co-market and offer DNA-encoded library (DEL) screening technologies to global customers, either as a standalone service or integrated into Aurigene's drug discovery offerings. The companies will also co-develop new DELs emphasizing novel chemical diversity and drug-likeness. Vipergen's high-fidelity DEL screening adds to Aurigene's small molecule discovery capabilities.PR NewswireVipergen Establishes Research Partnership with Bayer to Discover Novel Compoundsfor Pharmaceuticals and More Sustainable Crop Protection SolutionsVipergen, a Copenhagen-based provider of DNA-encoded library (DEL) drug discovery services, signed a multi-target research agreement with Bayer to discover novel small-molecule lead compounds for pharmaceuticals and sustainable crop protection solutions. Under the partnership, Vipergen will apply its Cellular Binder Trap Enrichment® (cBTE) in-living-cell screening platform to identify compounds binding to selected Bayer protein targets, with Bayer retaining exclusive global commercialization rights to all resulting products. Financial terms of the agreement were not disclosed.PR NewswireVipergen Establishes Research Partnership with Aligos Therapeutics Focused on DNA Encoded Library (DEL)-Based Drug Discovery for Viral Infections and Liver DiseasesVipergen has entered into a multi-target drug discovery agreement with Aligos Therapeutics to apply its DNA-encoded library technologies for identifying novel small-molecule compounds. Under the partnership, Aligos will select hits for development into therapeutics targeting viral infections and liver diseases while retaining exclusive global commercialization rights. Financial details of the agreement were not disclosed.BioSpaceVipergen Establishes Research Partnership with PhoreMost Focused on DNA Encoded Library (DEL)-Based Drug DiscoveryVipergen signed a multi-target drug discovery agreement with PhoreMost to use its DNA-encoded library technology to identify small-molecule compounds binding to PhoreMost protein targets. PhoreMost will select hits for oncology therapeutics and retain exclusive global commercialization rights, with financial terms undisclosed.PR NewswireVipergen Establishes Partnership with Anavo Therapeutics to Support Phosphatase-Targeted Discovery ProgramsVipergen, a Copenhagen-based provider of DNA-encoded library (DEL) drug discovery services, has signed a partnership agreement with Anavo Therapeutics to provide novel small-molecule drug leads against selected Anavo discovery targets. Under the agreement, Vipergen will apply its proprietary DEL technology platforms to support Anavo's proprietary phosphatase drug discovery programs focused on cancer treatments. Financial terms of the partnership were not disclosed.PR NewswireVipergen Publishes First Technology for Screening DNA-Encoded Small-Molecule Libraries (DELs) Inside Living CellsVipergen ApS announced the publication of a peer-reviewed study in the Journal of the American Chemical Society describing its Cellular Binder Trap Enrichment (cBTE) technology, the first method enabling DNA-encoded small-molecule library (DEL) screening inside living cells without requiring purified active target protein. The technology was validated by screening a 194 million-member DEL against three pharmaceutical protein targets in live Xenopus laevis oocytes, successfully identifying and validating multiple small-molecule hits for each target. Vipergen is now offering the cBTE platform as a service to biotechnology and pharmaceutical partners to accelerate drug discovery and reduce attrition rates.